Suppression of human a-foetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti a-foetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier
1985

Anti-AFP Antibody and Daunorubicin Conjugate Suppresses Tumor Growth

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): Y. Tsukada, K. Ohkawa, N. Hibi

Primary Institution: Hokkaido University School of Medicine

Hypothesis

Can an anti-alpha-fetoprotein antibody-daunorubicin conjugate effectively suppress the growth of human hepatocellular carcinoma in nude mice?

Conclusion

The aAFP-PLGA-DM conjugate shows potent anti-tumor activity against human AFP-producing tumors in nude mice.

Supporting Evidence

  • The conjugate showed a significant reduction in tumor growth compared to control groups.
  • Serum AFP levels were significantly lower in mice treated with the conjugate.
  • The study demonstrated that the conjugate effectively targeted AFP-producing tumors.

Takeaway

Researchers created a special medicine that combines an antibody with a cancer drug to help stop a type of liver cancer from growing in mice.

Methodology

The study involved treating nude mice with a conjugate of anti-AFP antibody and daunorubicin, measuring tumor growth and serum AFP levels.

Limitations

The study was conducted in nude mice, which may not fully represent human responses.

Participant Demographics

Nude mice were used in the study.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication